亿帆医药：2025年亿立舒在美采购订单已超4万支 且终端销售价格有较大幅度提升

Group 1 - The core viewpoint of the news is that Yifan Pharmaceutical is actively engaging with investors regarding its innovative drug Yilishu, focusing on its market launch in the US and sales expectations in China [1][2] - Yilishu is expected to achieve significant sales in China, with over 270,000 units projected for 2024 and net sales exceeding 500 million yuan [1] - The US market launch, initially planned for July 2024, has been delayed due to packaging issues and supply chain challenges, with a new shipment expected to arrive by mid-June 2025 [1][2] Group 2 - Acrotech, Yifan's partner, has revised its market expectations for Yilishu in the US after conducting detailed market research, leading to a binding purchase order for over 40,000 units for 2025 [2] - The terminal sales price (WAC) for Yilishu in the US has been significantly increased compared to previous expectations, with the final announcement to be made on the product's launch day [2] - Yifan is also exploring markets outside the US, with plans for Europe and Japan, where partnerships are being established for distribution and clinical trials [2]